ERBB2 and breast carcinoma: A correlation was also reported between PARP1 and BRCA1/2, and at the same time, with ERBB2 and PGR in the luminal B subgroup; such results can indicate that those breast cancer patients can receive Anti-HER2 Monoclonal Antibodies and anti-PGR drugs available in the clinic at present.